作者
Iain C Macdougall, Andreas J Bircher, Kai-Uwe Eckardt, Gregorio T Obrador, Carol A Pollock, Peter Stenvinkel, Dorine W Swinkels, Christoph Wanner, Günter Weiss, Glenn M Chertow, John W Adamson, Tadao Akizawa, Stefan D Anker, Michael Auerbach, Peter Bárány, Anatole Besarab, Sunil Bhandari, Ioav Cabantchik, Alan J Collins, Daniel W Coyne, Ángel LM De Francisco, Steven Fishbane, Carlo AJM Gaillard, Tomas Ganz, David J Goldsmith, Chaim Hershko, Ewa A Jankowska, Kirsten L Johansen, Kamyar Kalantar-Zadeh, Philip A Kalra, Bertram L Kasiske, Francesco Locatelli, Jolanta Małyszko, Gert Mayer, Lawrence P McMahon, Ashraf Mikhail, Elizabeta Nemeth, Amy Barton Pai, Patrick S Parfrey, Roberto Pecoits-Filho, Simon D Roger, Guy Rostoker, Jacques Rottembourg, Ajay K Singh, Itzchak Slotki, Bruce S Spinowitz, Der-Cherng Tarng, Francesca Tentori, Jorge E Toblli, Yusuke Tsukamoto, Nosratola D Vaziri, Wolfgang C Winkelmayer, David C Wheeler, Elena Zakharova
发表日期
2016/1/1
期刊
Kidney international
卷号
89
期号
1
页码范围
28-39
出版商
Elsevier
简介
Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of …
学术搜索中的文章
IC Macdougall, AJ Bircher, KU Eckardt, GT Obrador… - Kidney international, 2016